The clinical potential of PSAT1 modRNA for ischemic heart diseases is promising, offering benefits such as promoting cardiomyocyte proliferation, inhibiting oxidative stress and cell death, enhancing cardiac repair, and improving post-MI function. This evidence concerns the gene PSAT1 and coronary artery disorder.